Lutris updates
News & Announcements
Updates on our clinical programs, corporate milestones, and financing.
Lutris Pharma Presents Additional Positive Data from Its Phase 2 Trial of LUT014 Gel Demonstrating Significant Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at the ESMO Gastrointestinal Cancers Congress 2025
Lutris Pharma to Present Data from Its Phase 2 Trial of LUT014 Gel for the Treatment of Patients With EGFRI-Induced Acneiform Rash at the ESMO Gastrointestinal Cancers Congress 2025
Lutris Pharma Announces the Appointment of Seasoned Life Science Executive, Sumant Ramachandra, M.D., Ph.D., as Chief Executive Officer
Lutris Pharma Presents New Data from Its Completed Clinical Trial of LUT014 Gel Demonstrating Efficacy in Treating Acneiform Rash Associated with Use of Anti-EGFR Cancer Therapies at AACR Annual Meeting 2025
Lutris Pharma to Present at the American Association for Cancer Research Annual Meeting 2025
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness